Riskpilot← Back to searchSign inGet full accessJN BIOTECH ApS
APSActiveCVR 25325001Tuborg Boulevard 9, 3. tvOther personal service activities n.e.c. · NACE 9699Est. 2000— employees
Revenue 2025
DKK 90K
+222% vs 2024
EBITDA margin
100.0%
+222% vs 2024
Equity ratio
61.8%
Financial strength
Net profit 2025
DKK 104K
+71% vs 2024
| Revenue | DKK 90K | +222% |
| EBITDA | DKK 90K | +222% |
| Net profit | DKK 104K | +71% |
| Total assets | DKK 1,3M | +3% |
| Equity | DKK 821K | +15% |
| Employees | — | — |
Legal name
JN BIOTECH ApS
CVR number
25325001
Legal form
Anpartsselskab
NACE code
9699 · Other personal service activities n.e.c.
Founded
19. april 2000
Share capital
DKK 225.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at drive konsulentvirksomhed samt formueforvaltning.
Address
Tuborg Boulevard 9, 3. tv
Phone
+4541727930
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61 | 166 | 213 | 199 | 112 | 81 | 73 | 10 | 116 | 82 | 115 | 28 | 90 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 61 | 166 | 213 | 199 | 112 | 81 | 73 | 10 | 116 | 82 | 115 | 28 | 90 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 61 | 166 | 213 | 199 | 112 | 81 | 73 | 10 | 116 | 82 | 115 | 28 | 90 |
| Net financials | -95 | 8 | 6 | -11 | 18 | 53 | 12.721 | 11.561 | 1.997 | 352 | 78 | 50 | 45 |
| Profit before tax | -33 | 174 | 219 | 188 | 130 | 134 | 12.794 | 11.571 | 2.112 | 434 | 193 | 78 | 136 |
| Tax | 21 | 38 | 57 | 52 | 29 | 31 | -52 | 215 | 469 | 96 | 43 | 17 | 31 |
| Net profit | -55 | 136 | 162 | 136 | 100 | 103 | 12.846 | 11.355 | 1.643 | 338 | 150 | 61 | 104 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 278 | 434 | 578 | 782 | 887 | 1.016 | 13.896 | 25.392 | 16.490 | 3.634 | 1.213 | 1.293 | 1.328 |
| Equity | 233 | 369 | 532 | 668 | 768 | 872 | 13.718 | 25.073 | 15.667 | 3.005 | 656 | 717 | 821 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 45 | 65 | 47 | 114 | 118 | 144 | 178 | 318 | 823 | 629 | 557 | 577 | 507 |
| Total debt | 45 | 65 | 47 | 114 | 118 | 144 | 178 | 318 | 823 | 629 | 557 | 577 | 507 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122025
Equity ratio
61.8%
This company
38.2%
Market median
+62% vs market
20122025
Return on equity
12.7%
This company
18.4%
Market median
+31% vs market
20122025
Net profit margin
115.6%
This company
8.1%
Market median
+1327% vs market
20122025
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20122025
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-01-01 – 2020-06-30
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HM | Audit | 2000 | — | — |
JB Management | Management | 2019 | — | — |
JN Management | Management | 2007 | — | — |
JF | Audit | 2002 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
JBN Biotech ApS | Company | 90.0% | 100.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
JBN Biotech ApS
JN BIOTECH ApS Board members of JN BIOTECH ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Munkebo Christiansen | Audit | 0 companies |
| Jens Bredal Nielsen | Management | 0 companies |
| Jytte Nielsen | Management | 0 companies |
| Jacob Fromm Christiansen | Audit | 0 companies |